Literature DB >> 1641491

MRI-SPECT and PET-EEG findings on brain dysfunction in schizophrenia.

W Günther1.   

Abstract

1. In this article the author reviews a series of investigations on brain dysfunction in untreated schizophrenics using manumotor and music listening tasks as activation paradigms. Methods involved were EEG mapping, Single Photon Emission Computerized Tomography (SPECT; Xenon-133 inhalation method), Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET; 11-2-Deoxyglucose as tracer). 2. Major signs of brain dysfunction yielded a "nonreactivity" on both motor and music stimulation in patients displaying marked negative symptomatology, as shown consistently by EEG Mapping, SPECT and PET. In contrast, first-break patients with predominant "positive" and without underlying negative symptoms showed signs of "normal" to "diffuse hyperactivation" on such stimulations, as demonstrated by EEG and SPECT imaging methods. 3. Interestingly, MRI planimetry of the size of the corpus callosum (CC) corroborated the above findings, showing a significantly larger CC in "positive" than "negative" patients. 4. Together with functional imaging findings of other working groups and recent neuropathological theories we finally raise some speculative neurophysiological hypotheses on brain dysfunction in subgroups of schizophrenics, which might have direct implications for treatment and follow-up of these patients.

Entities:  

Mesh:

Year:  1992        PMID: 1641491     DOI: 10.1016/0278-5846(92)90052-g

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  1 in total

1.  Psychomotor disturbances in psychiatric patients as a possible basis for new attempts at differential diagnosis and therapy. V. Evaluation of psychomotor training programs in depressed patients.

Authors:  W Günther; P Streck; C Haag; U Klages; N Müller; I Hantschk; W Bender; M Gündürewa; R Günther
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1992       Impact factor: 5.270

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.